Medical Condition News

RSS

Micromet, MedImmune initiate MT111 Phase 1 trial in patients with advanced gastrointestinal cancer

MedImmune, the global biologics unit of AstraZeneca PLC and Micromet, today announced the initiation of a Phase 1 trial of MEDI-565 in patients with advanced gastrointestinal cancers. MEDI-565 is a BiTE antibody designed to direct a patient's T cells, the body's most potent killer cells, against cancer cells that express carcinoembryonic antigen.

13 Jan 2011

FDA accepts to review Fibrocell Science's azficel-T drug

Fibrocell Science, a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that the U.S. Food & Drug Administration has accepted for review the Company's complete response submission for azficel-T, proposed brand name laViv, for the treatment of moderate to severe nasolabial folds and wrinkles.

12 Jan 2011

New ultrasound elastography can help predict cancer in patients with BI-RADS category 4 masses

A new ultrasound technique is proving valuable in distinguishing malignant from benign breast lesions in some patients - results that could mean fewer unnecessary breast biopsies, a new study shows.

12 Jan 2011

AstraZeneca, CANCER RESEARCH UK enter strategic alliance to conduct experimental cancer drug trials

CANCER RESEARCH UK's drug development office has signed a Strategic Combinations Alliance with AstraZeneca to take combinations of experimental cancer drugs into early phase clinical trials.

12 Jan 2011

GSK, ChemoCentryx initiate '786 Phase III clinical trial for Crohn's disease

GlaxoSmithKline and ChemoCentryx, announced today that the first patient with Crohn's disease has initiated treatment in the initial pivotal induction study comparing Traficet-EN, now designated GSK1605786 ('786), to placebo.

12 Jan 2011

Study indicates disease's underlying causes in mice, finds compounds that normalize Alzheimer's brain

A Blanchette Rockefeller Neurosciences Institute study published today in the Journal of Neuroscience reveals underlying causes for the degeneration of synapses in Alzheimer's Disease and identifies promising pharmaceutical solutions for the devastating condition that affects more than 5 million people in the United States.

12 Jan 2011

FDA panel rejects new pancreatic enzyme replacement drug

Eli Lilly & Co did not win the support of the U.S. advisory panel on Wednesday for its one-of-its kind drug not made from pig enzymes to help certain pancreatic patients digest food. A Food and Drug Administration panel of outside experts in a 7-4 vote said they were not convinced the experimental medicine, known chemically as liprotamase, worked well enough for patients to absorb enough needed nutrients. One member of the panel abstained.

12 Jan 2011

Antibiotics for ear infection in kids better than watchful waiting: Study

Findings from two latest clinical trials reveal that a young child with ear infections recovers faster and more completely if doctors give antibiotics right away rather than waiting to see if the kid get better on his/her own. One of the studies was in the U.S. and one in Finland. Earlier it has been debated that for young children with middle ear infections or otitis media whether immediate antibiotic treatment was better than watchful waiting. Current treatment recommendations in the U.S., Canada, and Europe allow for a watch-and-wait approach to suspected middle ear infections in young children. Change is coming, predicts study leader Alejandro Hoberman, MD, of Children’s Hospital of Pittsburgh.

12 Jan 2011

New Down syndrome non-invasive test for ‘mums-to-be’ on the horizon

According to experts a simple DNA test for Down syndrome could save nearly all pregnant women from invasive tests like amniocentesis. Usually 3% to 5% of pregnant women in the UK or some 30,000 women have to undergo invasive tests like amniocentesis that increases the risk of miscarriage to 1%. The new DNA blood test could bring this down to 0.1%, according to a study in the British Medical Journal.

12 Jan 2011

Wright launches DARCO Foot & Ankle Plating System in Japan

Wright Medical Group, Inc., a global orthopaedic medical device company, today announced the launch of the DARCO® Foot & Ankle Plating System in Japan. The DARCO® Plating System consists of over 40 different locked plates specifically designed to meet the needs of foot and ankle surgeons. Wright has been selling the DARCO® Plating System in the United States and other key global markets since 2007.

12 Jan 2011

ZOLL announces successful conclusion of Circulation Improving Resuscitation Care trial

ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today the successful conclusion of the ZOLL-sponsored CIRC trial. The trial's Data Safety Monitoring Board (DSMB) closed enrollment when an analysis of the data showed the load-distributing band (AutoPulse® Non-invasive Cardiac Support Pump) to be equivalent to manual chest compressions.

12 Jan 2011

Endosense initiates enrollment in TactiCath Contact Force Ablation Catheter Study for Atrial Fibrillation

Endosense, a medical technology company focused on improving the efficacy, safety and accessibility of catheter ablation for the treatment of cardiac arrhythmias, has announced first patient enrollment in the TOCCASTAR (TactiCath Contact Force Ablation Catheter Study for Atrial Fibrillation) clinical study at Na Homolce Hospital, Prague, Czech Republic, by study investigator Petr Neuzil, M.D.

12 Jan 2011

Daiichi Sankyo and ArQule initiate enrollment in ARQ 197 Phase 3 trial in NSCLC

Daiichi Sankyo Company, Limited and ArQule, Inc. today announced that the first patient has been enrolled in the Phase 3 trial of ARQ 197, an investigational selective inhibitor of the c-Met receptor tyrosine kinase, in combination with erlotinib, for patients diagnosed with non-squamous, non-small cell lung cancer (NSCLC) who have received one or two prior systemic anti-cancer therapies.

12 Jan 2011

Best diet aid: Water

If you're like most people, losing those last few holiday pounds is high on your list of to-dos this month. Fortunately, one of the best diet aids is free, abundant and right at your fingertips: water.

12 Jan 2011

UnitedHealthcare selects Millennium as participating provider of pain management services

Millennium Laboratories, a leading provider of therapeutic drug monitoring and education to physicians and staff treating chronic pain, announced it will provide pain management and therapeutic drug monitoring services to physicians participating in UnitedHealthcare's national care provider network.

12 Jan 2011

Stem cell therapy enters anti-aging industry

While many scientists may state that stem cells are the key to longer and healthier lives, some are not waiting on the technology for that and are using it in the anti-aging industry to bring unmatched results in wrinkle removal. The ant-wrinkle and skin cream industry has been in a state of remission as far as advancements in the industry for decades.

12 Jan 2011

Lipoprotein receptor LRP1 also regulates food intake and energy balance in central nervous system: Study

A study by researchers at Mayo Clinic's campus in Florida and Washington University School of Medicine adds a new twist to the body of evidence suggesting human obesity is due in part to genetic factors. While studying hormone receptors in laboratory mice, neuroscientists identified a new molecular player responsible for the regulation of appetite and metabolism.

12 Jan 2011

Winter weather tips for people with high blood pressure

It's sad but true. Celebrity groundhog Punxsutawney Phil of PA and his relatives accurately predict the end or extension of winter only 39 percent of the time according to the United States National Climate Center.

12 Jan 2011

Dream team to build mind-controlled prosthetic devices

University of Houston researchers are helping the Pentagon build reliable mind-controlled prosthetic devices that military and civilian amputees can use the rest of their lives.

12 Jan 2011

Study shows delivering cancer drug in hydrophobic nanoparticle is a safe and effective prostate cancer therapy

Researchers at MIT and Brigham and Women's Hospital have shown that they can deliver the cancer drug cisplatin much more effectively and safely in a form that has been encapsulated in a nanoparticle targeted to prostate tumor cells and is activated once it reaches its target.

12 Jan 2011

Medical Condition News

Micromet, MedImmune initiate MT111 Phase 1 trial in patients with advanced gastrointestinal cancer

FDA accepts to review Fibrocell Science's azficel-T drug

New ultrasound elastography can help predict cancer in patients with BI-RADS category 4 masses

AstraZeneca, CANCER RESEARCH UK enter strategic alliance to conduct experimental cancer drug trials

GSK, ChemoCentryx initiate '786 Phase III clinical trial for Crohn's disease

Study indicates disease's underlying causes in mice, finds compounds that normalize Alzheimer's brain

FDA panel rejects new pancreatic enzyme replacement drug

Antibiotics for ear infection in kids better than watchful waiting: Study

New Down syndrome non-invasive test for ‘mums-to-be’ on the horizon

Wright launches DARCO Foot & Ankle Plating System in Japan

ZOLL announces successful conclusion of Circulation Improving Resuscitation Care trial

Endosense initiates enrollment in TactiCath Contact Force Ablation Catheter Study for Atrial Fibrillation

Daiichi Sankyo and ArQule initiate enrollment in ARQ 197 Phase 3 trial in NSCLC

Best diet aid: Water

UnitedHealthcare selects Millennium as participating provider of pain management services

Stem cell therapy enters anti-aging industry

Lipoprotein receptor LRP1 also regulates food intake and energy balance in central nervous system: Study

Winter weather tips for people with high blood pressure

Dream team to build mind-controlled prosthetic devices

Study shows delivering cancer drug in hydrophobic nanoparticle is a safe and effective prostate cancer therapy

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News